Search

Displaying results 381 - 390 of 3917 in total
  1. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

  2. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

  3. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623] … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

  4. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    [A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and

  5. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDSProducts: SULFASALAZINA 500 MG TABLETA CON CUBIERTA ENTÉRICA
  6. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

  7. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors.

  8. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    In the USA it is was approved in March, 2016 as Defitelio.

  9. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  10. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS